SAB Biotherapeutics Announces New Appointments to its Board of Directors
16.12.2020 15:27:00 EET | Business Wire | Press release
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal antibodies without the need for human serum, today announced the appointment of Mani Mohindru, PhD, and Mervyn Turner, PhD to its Board of Directors.
“We are excited to welcome Drs. Mohindru and Turner to our Board of Directors. Each industry executive brings a wealth of corporate strategy, drug development and financial expertise,” said Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics. “Both Drs. Mohindru and Turner are joining SAB at a pivotal time as we continue to advance a new class of immunotherapies that leverage the native human immune response and match the evolution of human disease. We look forward to their contributions as we develop our robust pipeline, spanning multiple therapeutic areas, using our novel technology platform.”
Dr. Mohindru is a senior biopharmaceutical executive with several years of industry leadership as well as Wall Street experience. Most recently, she was the CEO of CereXis, a clinical-stage biopharmaceutical company developing treatments for rare tumors. Previously, Dr. Mohindru was Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics (Nasdaq: CARA), a company focused on developing therapies for pruritus and pain. Earlier, she served as Chief Strategy Officer at Curis, Inc. (Nasdaq: CRIS), where she was instrumental in the development of overall strategy for its oncology focused pipeline. Dr. Mohindru also spent several years as an equity research analyst covering the biotechnology sector at ThinkEquity, LLC, Credit Suisse and UBS. She also co-founded Immtox LLC, a privately-held biotechnology company, and was a healthcare industry consultant at Axon Healthcare Partners and SAI Healthcare (acquired by IMS Health). Currently, she also serves as a Member of the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Dr. Mohindru received her PhD in Neurosciences from Northwestern University.
Dr. Mervyn Turner has nearly 35 years of experience in pharmaceutical drug discovery, research and development, licensing and business development, emerging markets strategy development and implementation. He currently operates his own consulting firm, MJ Turner Consulting, where he counsels biotech, pharma, venture capital and investment banking firms. He spent 27 years at Merck & Co. Inc., holding positions of increasing responsibility in Merck Research Laboratories before joining the company’s Executive Committee as Chief Strategy Officer. Since his retirement from Merck & Co., he is currently an Advisor to Bay City Capital, a San Francisco-based venture firm, to Bridge Medicines, a commercial incubator for early stage innovation based in New York City, and to Adagene, a China-based therapeutic antibody company. Dr Turner is also a member of the Board of EnGeneIC (Sydney, Australia), and the Chairman of the Board of LUNAC. He also serves on the Scientific Advisory Boards of Blade Therapeutics and Spinogenix. Additionally, Dr. Turner is a Senior Advisor to the Healthcare group of Lazard, a leading financial services and investment banking firm. He holds his PhD in Chemistry from the University of Sheffield.
“I am excited to have the opportunity to join the Board of SAB, to help foster the adoption of the company’s unique capabilities in meeting the therapeutic needs of both the current, and future pandemics,” said Mervyn Turner, PhD. “I also look forward to helping to drive the SAB platform into novel therapeutic areas outside infectious disease, where polyclonal antibody technology offers unique capabilities in areas of significant unmet medical need.”
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, specifically-targeted, high-potency, human polyclonal immunotherapies at commercial scale. SAB-185, a fully-human polyclonal antibody therapeutic candidate for COVID-19, is being developed with initial funding supported by the Biomedical Advanced Research Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services and the Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) Joint Project Lead for Enabling Biotechnologies (JPL-EB). In addition to COVID-19, the company’s pipeline also includes programs in Type 1 diabetes, organ transplant and influenza. For more information visit: www.sabbiotherapeutics.com or follow @SABBantibody on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005549/en/
Contact information
Melissa Ullerich
Tel: 605-695-8350
mullerich@sabbiotherapeutics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pantheon Expands Middle East Presence With New Abu Dhabi Office and Senior Regional Appointment30.9.2026 13:56:00 EEST | Press release
Pantheon, a leading global private markets firm with approximately $84bn in assets under management, today announced the expansion of its presence in the Middle East with the opening of its first office in ADGM, the international financial center based in Abu Dhabi, alongside the appointment of Firas Mallah as Managing Director and Head of Middle East. Demand for access to private equity, infrastructure, and private credit strategies continues to build among sophisticated investors across the Middle East, who recognize Pantheon for its 40-year track record of innovation and expertise across primaries, secondaries and co-investment opportunities. Secondaries – pioneered by Pantheon in 1988 – remains a defining thread across the platform: alongside its long-established private equity secondaries business, Pantheon has among the industry's first and largest private credit and infrastructure secondaries franchises, making it a strong partner in that space across the GCC. These strategies a
34% of Global Consumers Say They Are Worse Off Financially Than a Year Ago as Households Adapt to a New Era of Permanent Uncertainty, NIQ Finds30.9.2026 13:45:00 EEST | Press release
With over a third (34%) of global consumers saying they are financially worse off than they were a year ago, and another third (30%) saying they are financially better off, consumers are no longer waiting for economic conditions to improve. Around the world, households are adapting to a future where volatility remains a persistent reality, creating increasingly different financial outcomes, spending priorities, and pathways to growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930542911/en/ NIQ's Consumer Outlook: Guide to 2027 These findings come from NielsenIQ’s (NYSE: NIQ) latest global Consumer Outlook survey of more than 21,000 respondents across 31 countries, combined with NIQ's measurement of real-world purchasing behavior. The research reveals that economic uncertainty is no longer a temporary disruption, but a defining feature of how consumers make decisions. Findings include: 34% of global consumers globally
Neutrogena ® , Aveeno ® , and Regaine ® Present New Scientific Evidence Demonstrating How Science-Backed Ingredients Support Healthy Skin and Hair30.9.2026 13:45:00 EEST | Press release
Neutrogena®, Aveeno®, and Regaine®* will present 12 new scientific data sets at the 35th European Academy of Dermatology and Venereology (EADV) Congress taking place September 30th through October 3rd in Vienna. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930489298/en/ New Neutrogena science showcased at EADV 2026 in Vienna, Austria Abstracts presented will share new evidence demonstrating how science-backed ingredients including niacinamide, trehalose, colloidal oat and 5% minoxidil can help address some of the most common skin and hair concerns consumers experience, including acne, oily skin, dry skin, hyperpigmentation, eczema, UV-related skin damage and androgenetic alopecia. The findings reinforce a growing body of evidence showing that innovative formulations can deliver benefits beyond traditional expectations by helping protect and strengthen the skin barrier, improve visible skin concerns, and support hair reg
Compass Pathways Appoints Kelley Boucher as Chief People Officer30.9.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today. This appointment strengthens the Compass executive team as the company continues to scale in support of its mission to bring the first classic psychedelic treatment to the field of psychiatry. In this role, Ms. Boucher will oversee the Company’s people strategy, with an initial focus on guiding its planned evolution towards the launch of COMP360 psilocybin, subject to FDA approval, in the first half of 2027. "We are thrilled to welcome Kelley to our executive team at this pivotal moment in Compass’ journey. As we prepare for our NDA submission in the fourth quarter of this year, we are closer than ever to achieving our goal of introducing an entirely new treatment model in mental health care with COMP360 psilocybin," said Kabir Nath, Chief Executive Officer a
NIQ Expands Google Relationship with Meridian Integration into NIQ Cadence™30.9.2026 13:30:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the expansion of its relationship with Google through the integration of Meridian, Google's open-source MMM framework, into NIQ Cadence™, NIQ's AI-native marketing effectiveness operating system. The strategic partnership gives marketers a single place to measure marketing performance and act on it, shortening the distance between insights and optimization. Marketing leaders are under growing pressure to prove the return on every media dollar, and traditional measurement has struggled to keep pace. In NIQ’s latest CMO Report, 74% of CMOs said they were under more scrutiny to prove marketing ROI, while just 9% felt they had adequate access to real-time insights. NIQ Cadence™ was built to help close the 65-point actionability gap between accountability and timeliness. Rather than treating measurement as a one-time event, the integration brings Meridian into NIQ Cadence™, a unified platform which brings data, models
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom